e-learning
resources
Vienna 2009
Monday, 14.09.2009
New aspects of inhalation therapy
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Dose emission from a formoterol aerolizer is dependent on inhalation flow and volume
S. Alaboud, K. Assi, H. Chrystyn (Bradford, Huddersfield, United Kingdom)
Source:
Annual Congress 2009 - New aspects of inhalation therapy
Session:
New aspects of inhalation therapy
Session type:
Thematic Poster Session
Number:
2038
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Alaboud, K. Assi, H. Chrystyn (Bradford, Huddersfield, United Kingdom). Dose emission from a formoterol aerolizer is dependent on inhalation flow and volume. Eur Respir J 2009; 34: Suppl. 53, 2038
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Interactions of pharmacotherapy and exercise training
Comparison of bronchodilator responsiveness in children with primary ciliary dyskinesia and cystic fibrosis
Reproducibility of inhaler use and pulmonary drug deposition in COPD
Related content which might interest you:
Tiotropium dose emission is influenced by the inhalation flow and the recommended two inhalations for each dose
Source: Eur Respir J 2005; 26: Suppl. 49, 125s
Year: 2005
In vitro
dosage emission for different flow rates from a combination of eformoterol and budesonide in a dry powder inhaler
Source: Eur Respir J 2001; 18: Suppl. 33, 134s
Year: 2001
Delivered dose and fine particle dose of aclidinium bromide 200 µg via the Genuair® inhaler are independent of flow rate within the working range of the device
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010
Effect of sequential nebulised salbutamol therapy on peak expiratory flow rate
Source: Eur Respir J 2005; 26: Suppl. 49, 507s
Year: 2005
Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers
Source: Eur Respir J 2001; 18: 780-783
Year: 2001
Flutide™ Diskus™ less consistent than Pulmicort® Turbuhaler® with respect to
in vitro
fine particle dose proportionality
Source: Eur Respir J 2001; 18: Suppl. 33, 157s
Year: 2001
Different inhalation volumes do not impact on the aerodynamics of aclidinium bromide delivered using the Genuair® inhaler
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010
Objective measurement of inhalation profiles in patients using metered dose inhalers (MDIs)
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011
Effect of changes in peak inspiratory flow on the dose of salbutamol delivered by nebulizers under simulated conditions
Source: International Congress 2018 – What’s new in lung function and exercise assessment in COPD?
Year: 2018
In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
A pMDI formulation of levosalbutamol produces an equivalent bronchodilator response as racemic salbutamol at half the dose
Source: Eur Respir J 2005; 26: Suppl. 49, 122s
Year: 2005
Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009
Peak inspiratory flow rate and the slope of the inhalation profile in dry powder inhalers (DPI)
Source: Eur Respir J 2001; 18: Suppl. 33, 69s
Year: 2001
Improvement in the drug delivery of salmeterol/fluticasone via a novel breath actuatedpressurized metered dose inhaler with a dose counter
Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies
Year: 2019
Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler®
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012
Pressurised metered dose inhalers (pMDIs) with integrated flow rate guidance.
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017
Two-tone trainer maintains a slow inhalation rate when using a metered dose inhaler (MDI)
Source: Eur Respir J 2005; 26: Suppl. 49, 47s
Year: 2005
Comparison of the safety relating to paradoxical bronchoconstriction of ipratropium bromide (IB) alone or combined with fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (CFC-MDI) in
Source: Eur Respir J 2002; 20: Suppl. 38, 246s
Year: 2002
Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD
Source: Eur Respir J 2003; 21: 86-94
Year: 2003
Dose- and exposure-response modeling to support development of formoterol fumarate (FF) metered dose inhaler (MDI) for COPD
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept